Picture supply: Getty Pictures
The Dr Martens (LSE:DOCS) share worth was the second-worst performer on the FTSE 250 yesterday (20 November), after the legendary boots, footwear and sandals maker reported its interim outcomes for the 26 weeks ended 28 September (H1 26).
The response of traders was notably disappointing given the group’s current share worth efficiency. In April, it recorded a 52-week low of 43p, as President Trump’s bulletins on tariffs created uncertainty for the group with its Asian-focused manufacturing operation. Since then — and previous to the publication of the outcomes — it had elevated almost 90%.
Yesterday, its share worth closed at 74p, having fallen 9.5% over the course of the day. Typically it’s laborious to consider that the group listed in January 2021 with an IPO worth of 370p.
So what brought about such a unfavorable response? To be sincere, I’m not likely certain. Okay, the outcomes weren’t superb however I don’t assume a near-10% fall’s warranted.
Supply: London Inventory Trade Group
Crunching the numbers
The group reported a 0.8% drop in H1 26 income in comparison with the identical interval a 12 months earlier. Nonetheless, its adjusted loss earlier than tax (LBT) improved by £7.2m to £9.4m. Traditionally, its efficiency has been closely weighted to the second half of every monetary 12 months. The same pattern’s anticipated for FY26.
Considerably, the gross revenue margin continues to rise. However at 65.3%, it’s now larger — or much like some luxurious manufacturers. How a lot of that is attributable to cost rises is unclear however the scope to proceed charging extra appears restricted. In FY18, its margin was 53.4%.
In comparison with a 12 months earlier, stock ranges have been £45.6m decrease or, expressed one other manner, 4 weeks’ much less inventory is now being held. Web debt (together with leases) fell from £348.7m to £302.3m over the identical interval.
The group’s maintained its interim dividend at 0.85p a share.
Going to plan
Most significantly, the group says it’s buying and selling in keeping with present expectations. Earlier than yesterday, analysts have been anticipating an adjusted revenue earlier than tax for FY26 of £53m-£60m.
This excludes any estimated influence from tariffs. The corporate’s now confirmed that these are prone to cut back earnings by “high single-digit” tens of millions, though round half of that is anticipated to be offset by mitigating actions together with “tight cost control, flexible product sourcing, and targeted adjustments to our USA pricing policy”.
To be sincere, I assumed the tariff influence would have been a lot greater.
Inexperienced shoots
Throughout all traces, pairs offered elevated by 1% to 4.7m. Additionally, income in America was up 6%.
This sounds constructive to me and doesn’t seem to justify yesterday’s response of traders. Though it’s early days, I feel there’s sufficient proof of a restoration to make the inventory one to think about.
Time will inform if these inexperienced shoots proceed to develop. And I acknowledge there are many different alternatives accessible to traders who wish to purchase beaten-down shares which may have turned the nook. Nonetheless, I’ve at all times had a little bit of a comfortable spot for Dr Martens. That’s why I hope it could recapture a few of its former glories.
